Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer’s disease: A phase 2, double‐blind, randomized, placebo‐controlled trial
| Autor: | Raymond Scott Turner, Dalila Ferrante, Jaeil Ahn, Michaeline Hebron, Abigail Lawler, Guiseppe Esposito, Sara Matar, Frank Berkowitz, Fernando Pagan, Elizabeth E. Mundel, Sanjana Mulki, Charbel Moussa, Wangke Shi, Xiong Jiang, Yasar Torres-Yaghi, Xiaoguang Liu, Nadia Yusuf, Nathan Starr |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Amyloid Epidemiology business.industry Health Policy Placebo-controlled study Safety tolerability Disease Double blind Psychiatry and Mental health Cellular and Molecular Neuroscience Developmental Neuroscience Nilotinib Internal medicine Medicine Neurology (clinical) Geriatrics and Gerontology business medicine.drug |
| Zdroj: | Alzheimer's & Dementia. 16 |
| ISSN: | 1552-5279 1552-5260 |
| DOI: | 10.1002/alz.044628 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|